Pancreatic cancer (PC), one of the most lethal solid tumors in humans, has a five-year survival rate of only 4%. Surgical treatment is the only accepted therapy with curative intent because the vast majority of these tumors are chemoresistant. Unfortunately, due to the aggressive nature of these tumors, fewer than 20% are resectable when the first symptoms occur. Novel therapies are required to overcome all these therapeutic issues, and the development of active nanocarriers represents an exciting opportunity to improve PC outcomes. The present review focuses on recent advances in the field of nanotechnology with application in PC treatment.
There have been continuous advances in nanoscience since the beginning of the 21st century, and the emerging field of computational nanomedicine, the development of nanomaterial-based sensors or the prominent biomedical engineering applications should be mentioned. Intestinal disorders causing prolonged inflammation of the digestive tract, largely known as inflammatory bowel disease (IBD), include Crohn’s disease (CD) and ulcerative colitis (UC), have seen a significant increase in incidence rates. Nanoparticle-based approaches to locally target therapy could help regulate immune responses and act as an anti-inflammatory in individual patients diagnosed with IBD. The results of the paper emphasize the major role that nanoparticle-mediated drug delivery has in IBD treatment, giving IBD patients in remission the chance for a more effective drug therapy with a decreased medication load.
Health is defined as the state characterized by a physical, psychological and social wellbeing. In the primary care practice - Individual Medical Practice Popa-Nedelcu Eusebiu MD, 80 patients with various types of depression were identified within 6 months, out of a database of approximately 4000 patients. The aforementioned 80 patients, aged between 35 and 88, were divided into 2 groups: 54 patients with depression and comorbid chronic conditions and 26 patients with depression, without comorbid chronic conditions.Each subject included in the study was assessed with 3 questionnaires: MADRS, M.I.N.I., General Assessment of Functioning (GAF).ResultsThe incidence of the depressive disorder in the studied time frame was 2%, and female gender subjects were more frequently involved. MADRS scores were significantly higher (scores higher than 30) in patients with depression associated with chronic conditions (cardiac, oncological, respiratory). The most frequent condition associated with depression was arterial hypertension (38%). Both MADRS scores, and GAF scores were influenced by antidepressant therapy. Patients under long- term treatment due to medical comorbid condition (74%) have a less satisfactory evolution and prognosis than those without somatic comorbid condition.ConclusionsDepression has a too large incidence in primary care. Family physicians need to be familiar with the features and monitoring of antidepressant therapy, as therapeutic compliance is the sine-qua-non prerequisite of remission and relapse prevention in depressive disorder.The severity, prognosis and evolution of patients with depression are more reserved in those with associated medical conditions, than in those without co-occuring conditions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.